Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
PaperCitations, authors & open-access status
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 382 citations, 2021 year and hybrid oa status.
382
Citations
2021
Year
hybrid
OA Status